Scientists have confirmed that hyperbaric oxygen therapy has a significant auxiliary therapeutic effect on COVID-19.

As early as several months ago, experts from both home and abroad published articles demonstrating that HBOT hyperbaric oxygen therapy has significant therapeutic effects as an adjunct treatment for COVID-19.

Hyperbaric oxygen therapy (HBOT) is widely used worldwide for the treatment of decompression sickness, carbon monoxide poisoning, and the rehabilitation of injuries and wounds. In addition, it has now been successfully employed globally as a symptomatic treatment for numerous neurological, vascular, respiratory, and inflammatory conditions, such as multiple sclerosis, stroke, migraine, cerebral palsy, Parkinson’s disease, arthritis, respiratory disorders, circulatory disorders, fibromyalgia, wounds, sports injuries, myogenic encephalopathy, and post-surgical recovery—often in combination with conventional medications. It has also been found to be highly beneficial as an adjunctive therapy when cancer patients undergo chemotherapy and radiation therapy.